BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 37261366)

  • 1. Human papillomavirus vaccination in low- and middle-income countries: progression, barriers, and future prospective.
    Ebrahimi N; Yousefi Z; Khosravi G; Malayeri FE; Golabi M; Askarzadeh M; Shams MH; Ghezelbash B; Eskandari N
    Front Immunol; 2023; 14():1150238. PubMed ID: 37261366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experiences and lessons learned from 29 HPV vaccination programs implemented in 19 low and middle-income countries, 2009-2014.
    Ladner J; Besson MH; Audureau E; Rodrigues M; Saba J
    BMC Health Serv Res; 2016 Oct; 16(1):575. PubMed ID: 27737666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Key decision-making factors for human papillomavirus (HPV) vaccine program introduction in low-and-middle-income-countries: Global and national stakeholder perspectives.
    Guillaume D; Waheed DE; Schlieff M; Muralidharan K; Vorsters A; Limaye R
    Hum Vaccin Immunother; 2022 Dec; 18(7):2150454. PubMed ID: 36485172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009-2013.
    Ladner J; Besson MH; Rodrigues M; Audureau E; Saba J
    BMC Public Health; 2014 Jun; 14():670. PubMed ID: 24981818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis.
    Bénard É; Drolet M; Laprise JF; Jit M; Prem K; Boily MC; Brisson M
    Lancet Glob Health; 2023 Jan; 11(1):e48-e58. PubMed ID: 36521952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National implementation of HPV vaccination programs in low-resource countries: Lessons, challenges, and future prospects.
    Tsu VD; LaMontagne DS; Atuhebwe P; Bloem PN; Ndiaye C
    Prev Med; 2021 Mar; 144():106335. PubMed ID: 33678232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papillomavirus (HPV) vaccination: from clinical studies to immunization programs.
    Murillo R; Ordóñez-Reyes C
    Int J Gynecol Cancer; 2019 Oct; 29(8):1317-1326. PubMed ID: 31455660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Status of HPV vaccine introduction and barriers to country uptake.
    Gallagher KE; LaMontagne DS; Watson-Jones D
    Vaccine; 2018 Aug; 36(32 Pt A):4761-4767. PubMed ID: 29580641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
    Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
    Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
    Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
    Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-Dose Human Papillomavirus Vaccination in Low- and Middle-Income Countries-Time for Implementation?
    Gallant D; Tummers P; Weyers S; Merckx M
    J Pediatr Adolesc Gynecol; 2021 Oct; 34(5):586-590. PubMed ID: 34144176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What works for human papillomavirus vaccine introduction in low and middle-income countries?
    Howard N; Gallagher KE; Mounier-Jack S; Burchett HED; Kabakama S; LaMontagne DS; Watson-Jones D
    Papillomavirus Res; 2017 Dec; 4():22-25. PubMed ID: 29179865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of human papillomavirus immunization in the developing world.
    Kane MA; Serrano B; de Sanjosé S; Wittet S
    Vaccine; 2012 Nov; 30 Suppl 5():F192-200. PubMed ID: 23199963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current global status & impact of human papillomavirus vaccination: Implications for India.
    Sankaranarayanan R; Bhatla N; Basu P
    Indian J Med Res; 2016 Aug; 144(2):169-180. PubMed ID: 27934795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
    Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
    J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Status of Human Papillomavirus Infection and Introduction of Vaccination to the National Immunization Program in Korea: an Overview.
    Kim MA; Han GH; Kim JH; Seo K
    J Korean Med Sci; 2018 Dec; 33(52):e331. PubMed ID: 30584412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer Prevention Begins in Middle School: The Personal Advantages of HPV Immunization in Males.
    Gordon J; Bail J
    NASN Sch Nurse; 2023 May; 38(3):114-120. PubMed ID: 36691362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Influencing the Cost-Effectiveness Outcomes of HPV Vaccination and Screening Interventions in Low-to-Middle-Income Countries (LMICs): A Systematic Review.
    Okeah BO; Ridyard CH
    Appl Health Econ Health Policy; 2020 Oct; 18(5):641-654. PubMed ID: 32468410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool.
    Hutubessy R; Levin A; Wang S; Morgan W; Ally M; John T; Broutet N
    BMC Med; 2012 Nov; 10():136. PubMed ID: 23146319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
    Jit M; Brisson M; Portnoy A; Hutubessy R
    Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.